US3773221029 - Common Stock
GLAUKOS CORP
NYSE:GKOS (10/29/2024, 7:12:43 PM)
After market: 137.75 0 (0%)137.75
+3.67 (+2.74%)
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 907 full-time employees. The company went IPO on 2015-06-25. The company develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672
P: 19493679600
CEO: Thomas W. Burns
Employees: 907
Website: https://www.glaukos.com
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on GKOS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: